Spinal dissemination in epithelioid glioblastoma can be diagnosed by cerebrospinal fluid cytology and liquid biopsy to detect V600E mutation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283864 | PMC |
| http://dx.doi.org/10.1002/ccr3.4551 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Fibroblast Growth Factor Receptor 3-Fatty Acid Synthase Gene Fusion in Recurrent Epithelioid Glioblastoma Linked to Aggressive Clinical Progression.
Curr Oncol
November 2024
Pediatric Hematology/Oncology, Hospital Infantil Universitario "Niño Jesús", Universidad Autónoma de Madrid, 28009 Madrid, Spain.
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median overall survival (OS) of 15-18 months despite standard treatments. Approximately 8% of GBM cases exhibit genomic alterations in fibroblast growth factor receptors (FGFRs), particularly FGFR1 and FGFR3. Next-generation sequencing techniques have identified various FGFR3 fusions in GBM.
View Article and Find Full Text PDFA patient-derived xenograft mouse platform from epithelioid glioblastoma provides possible druggable screening and translational study.
Am J Cancer Res
October 2024
Department of Medicine, Chang Gung University Taoyuan 33305, Taiwan.
Article Synopsis
- Glioblastoma is a difficult-to-treat brain cancer with a low survival rate, despite improvements in surgical and radiation therapies.
- Epithelioid glioblastoma (eGBM) is a rare subtype where patient-derived xenograft (PDX) models in mice show potential for drug testing and research, indicating consistent genetic abnormalities across tumors.
- Recent studies using PDX models identified effective treatments, like Palbociclib and Dabrafenib/Trametinib, which significantly reduced tumor size and highlighted the importance of continuing research for better diagnosis and treatment options.
A case of epithelioid glioblastoma with lung metastases in a young Cane Corso dog.
J Comp Pathol
November 2024
Institute of Infection, Veterinary and Ecological Sciences, Department of Veterinary Anatomy, Physiology and Pathology, University of Liverpool, Leahurst Campus, Neston, Wirral CH64 7TE, UK.
Astrocytomas are relatively common primary brain tumours of humans and companion animals. In dogs, they represent approximately 17-28% of primary central nervous system tumours. However, extracranial metastasis is extremely rare.
View Article and Find Full Text PDFPrognosis prediction via histological evaluation of cellular heterogeneity in glioblastoma.
Sci Rep
October 2024
Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.
Glioblastomas (GBMs) are the most aggressive types of central nervous system tumors. Although certain genomic alterations have been identified as prognostic biomarkers of GBMs, the histomorphological features that predict their prognosis remain elusive. In this study, following an integrative diagnosis of 227 GBMs based on the 2021 World Health Organization classification system, the cases were histologically fractionated by cellular variations and abundance to evaluate the relationship between cellular heterogeneity and prognosis in combination with O-6-methylguanine-DNA methyltransferase gene promoter methylation (mMGMTp) status.
View Article and Find Full Text PDFClinicopathological, immunohistochemical and therapeutic approaches on survival in patients with epithelioid glioblastoma: Institutional experience in the management of 58 patients.
Neurosurg Rev
October 2024
Medical Imaging Center, Guangdong Province, The First Affiliated Hospital of Jinan University, Tianhe District, No. 613, Huangpu Road West, Guangzhou, 510630, China.
Article Synopsis
- Epithelioid glioblastoma (Ep-GBM) is a rare and aggressive brain tumor variant, with a high recurrence rate and poor prognosis; there’s currently no established standard treatment for it.
- In a study of 58 Ep-GBM cases, common symptoms included headaches and dizziness, and the median survival rates were 12.7 months for progression-free survival and 29.1 months overall; reoperation after recurrence notably improved survival time.
- Key factors influencing survival included tumor spread before initial surgery, the number of adjuvant temozolomide cycles received, and radiotherapy; extending the Stupp regimen with more temozolomide cycles could enhance outcomes for patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!